arrow
BackJournal Details
Annals of Oncology cover

Annals of Oncology

IF65.4
Papers34363
Citations64106
Journal Papers 67924
Publication Date
Efficacy of Cryotherapy in Preventing Taxane-Induced Neuropathy: The CryoPac Randomised Controlled Trial.
delete2026-10-06
delete0
deleteOAAI
deleteM.E. Lendorf; M.B. Bille; S.M. Krog; F.L. Kruse; L.M. Heining; C.W. Juul; R. Gravesen; S. Winther; E.V. Frandsen; A.V. Lendorf; H. Danø; A.S. Knoop; H. Pia; H. Tankisi; S. Birk; A.B. Jensen
deleteShare
deleteSave
Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study
delete2026-09-29
delete0
PREAI
deleteD.F. McDermott; S. Signoretti; J.-L. Lee; F. Donskov; S.S. Tykodi; P. Tomczak; G.A. Bjarnason; J.M.G. Larkin; M.D. Kochenderfer; R.A. Gafanov; R. Cristescu; J. Markensohn; M. Nebozhyn; Y. Zhang; X. Peng; K. Rodriguez-Lopez; J. Burgents; R.F. Perini; M.B. Atkins
deleteShare
deleteSave
SKYSCRAPER-07: Falling Short of the Top
delete2026-09-24
delete0
PREAI
deleteS.S. Kim; N.V. Uboha
deleteShare
deleteSave
Is it time to reassess standard toxicity and patient reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)?
delete2026-09-15
delete0
PREAI
deleteE. Nally; J. Lyon; M. Regan; B. Rini; M. Voss; M.B. Atkins; T. Powles; D.F. McDermott
deleteShare
deleteSave
The return of the adult thymus in radiation oncology?
delete2026-08-28
delete0
PREAI
deleteA. Levy; D. Morel; L. Meziani; M. Mondini; A. Shrebati; A. Botticella; C. Le Péchoux; C. Robert; E. Deutsch
deleteShare
deleteSave
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study
delete2026-08-26
delete0
PREAI
deleteN.B. Haas; T.B. Powles; P. Tomczak; S.H. Park; B. Venugopal; S.N. Symeonides; T. Ferguson; Y-H. Chang; J-L. Lee; P. Sawrycki; N. Sarwar; H. Gurney; M. Gross-Goupil; J.M. Burke; G. Doshi; J. Cornell; J.E. Burgents; R.F. Perini; T.K. Choueiri
deleteShare
deleteSave
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
delete2026-08-21
delete0
PREAI
deleteH. Wakelee; J.D. Spicer; S. Gao; M. Liberman; M. Tsuboi; T. Kato; K.-N. Chen; C. Dooms; M. Majem; G.L. Martinengo; O. Bylicki; D. Rodríguez-Abreu; B. Halmos; D.R. Jones; J.E. Chaft; M. Reck; E. Jensen; S.M. Keller; A. Samkari; M.C. Garassino
deleteShare
deleteSave
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
delete2026-08-21
delete0
deleteOAAI
deleteR-H. Xu; B.C. Cho; M. Chen; K. Muro; L. Wyrwicz; B. Li; S. Gao; C. Hsu; A. Turpin; F. Lordick; E. Cha; Q. Wu; S. Kim; J. Cai; L. Zhang; J. Fan; L. Wang; K. Sully; L. Wang; K. Goodman
deleteShare
deleteSave
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
delete2026-08-18
delete0
PREAI
deleteF. Facchinetti; L. Friboulet; L. Liao; M. Peroni; S. Nakazawa; L. Zullo; M. Aldea; F. Pecci; M. Makarem; I. Alonso Garcia; R. Minari; B. Tuladhar; K. Ngo; A. Da Silva; L. Bigot; I. Odintsov; M.K.A. Koivu; A. Leonetti; J. Samaniego; E. Bernard
deleteShare
deleteSave
Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)
delete2026-08-17
delete0
deleteOAAI
deleteA.Y. Zhang; H. Thomas; S. Begbie; L. Cheung; K.N. Chi; S. Chowdhury; M. Frydenberg; C. Herberstein; L.G. Horvath; A.M. Joshua; N.J. Lawrence; G. Marx; J. McCaffrey; R. McDermott; R.A. McLaughlin; S.A. North; F. Parnis; W. Parulekar; D.W. Pook; M.N. Reaume
deleteShare
deleteSave
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
delete2026-08-10
delete0
deleteOAAI
deleteK. Kato; J. Ajani; Y. Doki; J. Xu; L. Wyrwicz; S. Motoyama; T. Ogata; H. Kawakami; C-H. Hsu; A. Adenis; F. el Hajbi; M. Di Bartolomeo; M. Ignez Braghiroli; E. Holtved; T. Makino; M. Blum Murphy; J. Zhang; P. Sharma; B. He; M. Lei
deleteShare
deleteSave
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation
delete2026-08-06
delete0
PREAI
deleteH.A. Wakelee; M-J. Ahn; J. Bradley; S. Popat; K. Kelly; A-M. Baird; O. Ozyilkan; J. Yu; S.Y. Lee; N. Yanagitani; M. Johnson; A. Sánchez-Hernández; A. Szczesna; K. Cuppens; E. Yao; C. Parsons; C. Matheny; Z. Zhang; M.N. White; J.J. Hsu
deleteShare
deleteSave
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)☆
delete2026-07-24
delete0
PREAI
deleteK. Kalinsky; W.E. Barlow; H.B. Pathak; R.V. Puri; A. Mitra; T. Home; J. Gralow; K.S. Albain; D.F. Hayes; S. Delaloge; N.U. Lin; E.A. Perez; L.J. Goldstein; S.K.L. Chia; P. Rastogi; A.F. Schott; E. Brain; J.-Y. Pierga; J.-M. Ferrero; S. Shak
deleteShare
deleteSave